Sarcopenia in Liver Transplantation

Montgomery, John R.; Englesbe, Michael J.

doi:10.1007/s40472-019-0223-3

Cited by 12 publications

(8 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The different cut‐off thresholds used to define sarcopenia for each of the included studies are listed in Table 2 . 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 LMM was measured via dual‐energy X‐ray absorptiometry (six studies), 7 , 31 , 34 , 39 , 42 , 45 bioelectrical impedance analysis (10 studies), 8 , 32 , 33 , 38 , 40 , 41 , 43 , 44 , 46 , 47 and computed tomography (CT, six studies). 6 , 29 , 30 , 35 , 36 , 37 LMS was measured by HGS (14 studies).…”

Section: Resultsmentioning

confidence: 99%

Diagnosis, prevalence, and outcomes of sarcopenia in kidney transplantation recipients: A systematic review and meta‐analysis

Zhang

Shi

Zou

et al. 2022

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

The prevalence of sarcopenia and its clinical predictors and clinical impact vary among kidney transplant recipients (KTRs), in part because of different diagnostic criteria. This study aimed to assess the reported diagnosis criteria of sarcopenia and compare them in terms of prevalence, clinical predictors, and impact of sarcopenia. The Medline, Embase, and Cochrane Library were searched for the full-length reports published until 28 January 2022. The subgroup analysis, meta-regression, and sensitivity analysis were performed and heterogeneity was assessed using the I 2 . A total of 681 studies were retrieved, among which only 23 studies (including 2535 subjects, 59.7% men, mean age 49.8 years) were eventually included in the final analysis. The pooled prevalence in these included studies was 26% [95% confidence interval (95% CI): 20-34%, I 2 = 93.45%], including 22% (95% CI: 14-32%, I 2 = 88.76%) in men and 27% (95% CI: 14-41%, I 2 = 90.56%) in women (P = 0.554 between subgroups). The prevalence of sarcopenia diagnosed using low muscle mass was 34% (95% CI: 21-48%, I 2 = 95.28%), and the prevalence of using low muscle mass in combination with low muscle strength and/or low physical performance was 21% (95% CI: 15-28%, I 2 = 90.37%) (P = 0.08 between subgroups). In meta-regression analyses, the mean age (regression coefficient: 1.001, 95% CI: 0.991-1.011) and percentage male (regression coefficient: 0.846, 95% CI: 0.367-1.950) could not predict the effect size. Lower body mass index (odds ratio (OR): 0.57, 95% CI: 0.39-0.84, I 2 = 61.5%), female sex (OR: 0.31, 95% CI: 0.16-0.61, I 2 = 0.0%), and higher age (OR: 1.08, 95% CI: 1.05-1.10, I 2 = 10.1%) were significantly associated with a higher risk for sarcopenia in KTRs, but phase angle (OR: 0.81, 95% CI: 0.16-4.26, I 2 = 84.5%) was not associated with sarcopenia in KTRs. Sarcopenia was not associated with rejections (risk ratio (RR): 0.67, 95% CI: 0.23-1.92, I 2 = 12.1%), infections (RR: 1.03, 95% CI: 0.34-3.12, I 2 = 87.4%), delayed graft functions (RR: 0.81, 95% CI: 0.46-1.43, I 2 = 0.0%), and death (RR: 0.95, 95% CI: 0.32-2.82, I 2 = 0.0%) in KRTs. Sarcopenia was found to be very common in KRTs. However, we have not found that sarcopenia had a negative impact on clinical health after kidney transplantation. Large study cohorts and multicentre longitudinal studies in the future are urgently needed to explore the prevalence and prognosis of sarcopenia in kidney transplant patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Diagnosis, prevalence, and outcomes of sarcopenia in kidney transplantation recipients: A systematic review and meta‐analysis

Zhang

Shi

Zou

et al. 2022

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

show abstract

“…Elucidating the role of TGR5 in CLD-related sarcopenia in our experimental model might have clinical implications. As previously mentioned, sarcopenia is a critical prognosis determinant in patients with advanced CLD, serving as an independent predictor of mortality and adverse outcomes both in the transplant waiting list and in the post-transplant setting [11,48]. Thus, strategies to ameliorate sarcopenia in patients with CLD may have a beneficial clinical impact.…”

Section: Discussionmentioning

confidence: 99%

Sarcopenia Induced by Chronic Liver Disease in Mice Requires the Expression of the Bile Acids Membrane Receptor TGR5

Ábrigo

Campos

González

et al. 2020

IJMS

View full text Add to dashboard Cite

Sarcopenia is a condition of muscle dysfunction, commonly associated with chronic liver disease (CLD), characterized by a decline in muscle strength, the activation of the ubiquitin-proteasome system (UPS), and oxidative stress. We recently described a murine model of CLD-induced sarcopenia by intake of hepatotoxin 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC), which presents an increase in plasma bile acids (BA). BA induced skeletal muscle atrophy through a mechanism dependent on the Takeda G protein-coupled receptor 5 (TGR5) receptor. In the present study, we evaluated the role of TGR5 signaling in the development of sarcopenia using a model of DDC-induced CLD in C57BL6 wild-type (WT) mice and mice deficient in TGR5 expression (TGR5−/− mice). The results indicate that the decline in muscle function and contractibility induced by the DDC diet is dependent on TGR5 expression. TGR5 dependence was also observed for the decrease in fiber diameter and sarcomeric proteins, as well as for the fast-to-slow shift in muscle fiber type. UPS overactivation, indicated by increased atrogin-1/MAFbx (atrogin-1) and muscle RING-finger protein-1 (MuRF-1) protein levels and oxidative stress, was abolished in tibialis anterior muscles from TGR5−/− mice. Our results collectively suggest that all sarcopenia features induced by the DDC-supplemented diet in mice are dependent on TGR5 receptor expression.

show abstract

“…We used the presence of low muscle mass based on a single skeletal muscle mass measurement for the definition of sarcopenia, aiming to capture the shrinking component of PFP developed by Fried et al 11 This definition is consistent with most sarcopenia studies in transplant populations 25,26 …”

Section: Methodsmentioning

confidence: 99%

Revision of frailty assessment in kidney transplant recipients: Replacing unintentional weight loss with CT-assessed sarcopenia in the physical frailty phenotype

Chen

Shafaat

Liu

et al. 2022

American Journal of Transplantation

View full text Add to dashboard Cite

Kidney transplantation (KT) experts did not support the use of subjective unintentional weight loss to measure shrinking in the physical frailty phenotype (PFP); a clinically feasible and predictive measure of shrinking is needed. To test whether unintentional weight loss could be replaced by an assessment of sarcopenia using existing CT scans, we performed a prospective cohort study of adult KT recipients with original PFP (oPFP) measured at admission (December 2008–February 2020). We ascertained sarcopenia by calculating skeletal muscle index from available, clinically obtained CTs within 1‐year pre‐KT (male < 50 cm2/m2; female < 39 cm2/m2) and combined it with the original four components to determine new PFP (nPFP) scores. Frailty was classified by frailty score: 0: non‐frail; 1–2: pre‐frail; ≥3: frail. Mortality and graft loss hazard ratios (HRs) were estimated using adjusted Cox proportional hazard models. Model discrimination was quantified using Harrell's C‐statistic. Among 1113 recipients, 18.6% and 17.1% were frail by oPFP and nPFP, respectively. Compared to non‐frail recipients, frail patients by either PFP had higher risks of mortality (oPFP HR = 1.67, 95% CI: 1.07–2.62, C = 0.710; nPFP HR = 1.68, 95% CI: 1.06–2.66, C = 0.710) and graft loss (oPFP HR = 1.67, 95% CI: 1.17–2.40, C = 0.631; nPFP HR = 1.66, 95% CI: 1.15–2.40, C = 0.634) with similar discriminations. oPFP and nPFP are equally useful in risk prediction for KT recipients; oPFP may aid in screening patients for pre‐KT interventions, while nPFP may assist in nuanced clinical decision‐making.

show abstract

Sarcopenia in Liver Transplantation

Cited by 12 publications

References 77 publications

Diagnosis, prevalence, and outcomes of sarcopenia in kidney transplantation recipients: A systematic review and meta‐analysis

Diagnosis, prevalence, and outcomes of sarcopenia in kidney transplantation recipients: A systematic review and meta‐analysis

Sarcopenia Induced by Chronic Liver Disease in Mice Requires the Expression of the Bile Acids Membrane Receptor TGR5

Revision of frailty assessment in kidney transplant recipients: Replacing unintentional weight loss with CT-assessed sarcopenia in the physical frailty phenotype

Contact Info

Product

Resources

About